Bio-Rad Laboratories, Inc. (BIO-B) Key Metrics
BIO-B valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $9.74B
- Enterprise value
- $9.81B
- P/E (TTM)
- 46.2
- Forward P/E
- 39.8
- PEG ratio
- 1.21
- Price / sales
- 3.8
- Price / book
- 1.4
- EV / EBITDA
- 17.3
- Dividend yield
- —
- Beta
- 1.07
BIO-B key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBIO-B returns How much profit the business earns on the capital it uses.
BIO-B financial health Debt, liquidity and how easily interest is covered.
BIO-B efficiency & capital use Working capital cycle and where the cash goes.
BIO-B returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BIO-B debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BIO-B cash returned to shareholders
BIO-B key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $310.70 | $325.60 | $320.65 | — | $722.91 | $574.15 | $369.60 | $230.00 | $238.25 | $183.15 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 10.8% | −24.1% | −6.9% | −31.1% | 36.1% | 48.8% | 36.0% | 10.4% | 4.2% | 1.1% |
| Return on invested capital (ROIC) | 3.0% | 2.9% | 3.0% | 3.4% | 3.5% | 4.5% | 4.0% | −2.5% | 4.9% | 1.7% |
| Return on assets (ROA) | 7.6% | −17.0% | −4.9% | −23.2% | 27.7% | 36.4% | 25.8% | 7.3% | 2.8% | 0.7% |
| Return on tangible assets | 7.7% | −21.3% | −5.5% | −28.4% | 24.7% | 30.6% | 23.1% | 6.9% | 3.2% | 0.9% |
| Free cash flow margin | 14.5% | 10.4% | 8.2% | 2.9% | 18.3% | 18.7% | 15.5% | 6.8% | −0.5% | 3.6% |
| Income quality (OCF / net income) | 0.70 | — | — | — | 0.16 | 0.15 | 0.26 | 0.79 | 0.91 | 7.68 |
| Financial health | ||||||||||
| Total debt | $1.53B | $1.37B | $1.41B | $1.39B | $223.4M | $225.7M | $651.2M | $439.4M | $435.0M | $434.5M |
| Cash & short-term investments | $1.54B | $1.66B | $1.61B | $1.79B | $869.9M | $991.1M | $1.11B | $844.8M | $755.0M | $839.4M |
| Net debt | −$11.7M | −$289.8M | −$201.6M | −$402.6M | −$646.5M | −$765.4M | −$463.5M | −$405.4M | −$320.0M | −$404.9M |
| Debt / equity | 0.21 | 0.21 | 0.16 | 0.14 | 0.02 | 0.02 | 0.11 | 0.11 | 0.15 | 0.17 |
| Debt / assets | 0.14 | 0.15 | 0.11 | 0.10 | 0.01 | 0.02 | 0.08 | 0.08 | 0.10 | 0.11 |
| Net debt / EBITDA | −0.01 | — | — | — | −0.12 | −0.15 | −0.19 | −0.60 | −1.19 | −1.96 |
| Current ratio | 5.62 | 6.48 | 5.83 | 5.55 | 2.92 | 3.39 | 2.41 | 4.49 | 3.93 | 3.91 |
| Quick ratio | 4.19 | 4.85 | 4.34 | 4.29 | 2.08 | 2.40 | 1.80 | 3.19 | 2.75 | 2.80 |
| Interest coverage | 5.5 | 5.5 | 6.8 | 12.7 | 322.6 | 19.3 | 9.8 | -4.5 | 5.1 | 2.3 |
| Working capital | $2.39B | $2.56B | $2.53B | $2.59B | $1.31B | $1.51B | $1.27B | $1.57B | $1.47B | $1.37B |
| Invested capital | $7.44B | $6.28B | $8.54B | $9.21B | $13.04B | $9.11B | $5.29B | $3.61B | $2.61B | $2.17B |
| Tangible asset value | $6.70B | $5.87B | $8.01B | $8.88B | $13.08B | $9.39B | $5.35B | $3.67B | $2.25B | $1.94B |
| Net current asset value | −$216.7M | $235.5M | −$509.6M | −$728.4M | −$2.12B | −$952.8M | −$73.6M | $432.7M | $633.9M | $573.2M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $100.10B | $68.18B | $35.28B | $20.2M | $3.83B | — | $4.4M | — |
| Share buybacks (net) | $295.5M | $203.6M | $428.7M | $215.7M | $50.0M | $100.0M | $28.0M | $48.9M | $2.9M | $0 |
| Dividend payout ratio | — | — | — | — | 829.3% | 0.5% | 217.8% | — | 3.8% | — |
| Dividends + buybacks / free cash flow | 78.9% | 76.5% | — | — | — | 25.2% | — | 31.4% | — | 0.0% |
| Capex / revenue | 6.1% | 7.4% | 5.9% | 4.1% | 4.6% | 4.3% | 4.3% | 5.7% | 5.3% | 6.8% |
| Capex / operating cash flow | 29.6% | 41.5% | 41.8% | 58.7% | 20.0% | 18.6% | 21.5% | 45.5% | 110.6% | 65.5% |
| Capex / depreciation | 0.95 | 1.25 | 1.07 | 0.83 | 0.97 | 0.78 | 0.73 | 0.94 | 0.77 | 0.99 |
| Stock-based compensation / revenue | 2.2% | 2.4% | 2.3% | 2.2% | 1.8% | 1.6% | 1.5% | 1.2% | 1.1% | 1.0% |
| R&D / revenue | 9.9% | 11.5% | 9.3% | 9.2% | 8.9% | 8.6% | 8.8% | 8.7% | 11.6% | 10.0% |
| SG&A / revenue | 32.7% | 31.7% | 31.7% | 29.5% | 30.1% | 31.4% | 35.7% | 36.5% | 37.4% | 39.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 65.4 | 66.9 | 67.2 | 59.8 | 52.6 | 58.2 | 62.0 | 68.3 | 70.7 | 67.4 |
| Days of inventory on hand | 220.9 | 236.7 | 220.0 | 190.9 | 169.7 | 193.8 | 196.9 | 201.8 | 210.1 | 199.2 |
| Days payables outstanding | 37.0 | 41.0 | 41.0 | 40.9 | 40.0 | 40.6 | 39.7 | 44.1 | 50.3 | 50.1 |
| Cash conversion cycle (days) | 249.3 | 262.7 | 246.2 | 209.7 | 182.4 | 211.4 | 219.2 | 226.0 | 230.5 | 216.5 |
| Receivables turnover | 5.59 | 5.45 | 5.43 | 6.10 | 6.93 | 6.27 | 5.89 | 5.34 | 5.16 | 5.42 |
| Payables turnover | 9.87 | 8.90 | 8.90 | 8.92 | 9.13 | 8.99 | 9.19 | 8.27 | 7.25 | 7.28 |
| Inventory turnover | 1.65 | 1.54 | 1.66 | 1.91 | 2.15 | 1.88 | 1.85 | 1.81 | 1.74 | 1.83 |
| Asset turnover | 0.26 | 0.24 | 0.21 | 0.18 | 0.19 | 0.24 | 0.34 | 0.46 | 0.53 | 0.55 |
| Average receivables | $462.5M | $470.8M | $491.8M | $459.1M | $421.5M | $406.0M | $392.6M | $428.6M | $418.6M | $381.9M |
| Average payables | $125.7M | $133.4M | $139.8M | $138.5M | $140.7M | $123.2M | $114.7M | $128.8M | $134.1M | $127.8M |
| Average inventory | $750.4M | $770.2M | $749.9M | $645.8M | $597.2M | $588.1M | $568.9M | $589.3M | $559.9M | $507.6M |
| Intangibles / total assets | 7.1% | 7.5% | 6.0% | 5.5% | 3.4% | 3.8% | 5.1% | 6.3% | 15.9% | 16.6% |
Computed from BIO-B's annual financial statements (latest annual report filed February 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BIO-B valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 46.2 and the forward P/E is 39.8. Bio-Rad Laboratories earned a return on equity of 10.8% and a return on invested capital of 3.0% in fiscal 2025. It ended the year with $1.5 billion of debt and $1.5 billion in cash and short-term investments, a net cash position of $11.7 million. It returned $295.5 million to shareholders: $0 in dividends and $295.5 million in share buybacks, 79% of free cash flow.
See the BIO-B income statement, the BIO-B chart for price history, or the BIO-B stock overview for the latest quote and news.
BIO-B key metrics FAQ
What is Bio-Rad Laboratories's P/E ratio?
Bio-Rad Laboratories's trailing P/E ratio is 46.2 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 39.8. At the end of fiscal 2025 it was —.
What is Bio-Rad Laboratories's return on equity?
Bio-Rad Laboratories's return on equity (ROE) was 10.8% in fiscal 2025: net income of $759.9 million on average shareholders' equity of $7.0 billion.
What is Bio-Rad Laboratories's ROIC?
Bio-Rad Laboratories's return on invested capital was 3.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Bio-Rad Laboratories have?
Bio-Rad Laboratories had total debt of $1.5 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.21 and more cash than debt.
Does Bio-Rad Laboratories buy back its shares?
Yes. Bio-Rad Laboratories spent $295.5 million on net share repurchases in fiscal 2025.
What is Bio-Rad Laboratories's current ratio?
Bio-Rad Laboratories's current ratio was 5.62 at the end of fiscal 2025: current assets were 5.62 times current liabilities.